ASCLS eNewsBytes

• Stem Cells Improve Sight — and Open New Possibilities September 14, 2026
  A new stem cell treatment for a progressive eye disorder has enabled patients to read five additional lines on a standard eye chart, providing new hope for individuals who have exhausted existing treatments. The method merges eye-surface stem cells with supporting cells to enhance their survival after transplantation.
• FDA Grants Final Approval to Cabozantinib Capsule Formulation September 14, 2026
  The FDA has granted final approval for a laurylsulfate salt formulation of cabozantinib, allowing commercialization in the U.S. This new formulation can be administered without food, eliminating the strict fasting requirements of the original tablet formulation.
• FDA Approves Sevabertinib for HER2-Mutant Non-Small Cell Lung Cancer September 14, 2026
  The U.S. FDA has granted accelerated approval for sevabertinib, a targeted kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer with HER2 tyrosine kinase domain activating mutations, identified by an FDA-authorized test.
• When the Climate Shifts, So Do the Pathogens (And So Should We) September 14, 2026
  Climate change increases the risk of zoonotic diseases, which are infectious diseases that can transfer between animal species. The term zoonoses may be unfamiliar to many, but recent events, such as the SARS-CoV-2 pandemic linked to bat populations in Asia, highlight the global impact of these diseases.
• DISC-3405 Reduces Phlebotomy Burden in Polycythemia Vera September 14, 2026
  Early results from the phase 2 RESTORE-PV trial indicate that the investigational monoclonal antibody DISC-3405 may reduce the necessity for phlebotomy and assist in stabilizing hematocrit levels in patients with polycythemia vera.